Since 2008, downstream purification issues have become progressively more acute problems for biomanufacturers. But that’s begun to change this year, according to results from BioPlan Associates’ 9th ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Downstream processing encompasses the sequence of operations required to isolate, purify and formulate a biopharmaceutical product from crude biological feedstock. Following cell culture or ...

Authors: Nick Koumakis and Rut Besseling. Protein aggregation in downstream processing (DSP) is a product-quality concern and major process-performance issue. Aggregate populations can reduce ...